文献速递妇科肿瘤

Gemogenovatucel-T(Vigil)一线维持免疫治疗III/IV期卵巢癌的2b期随机双盲安慰剂对照研究

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial.
PubMed 文献 · Lancet Oncol · 2020-01-01

VITAL研究是一项在美国25家医院开展的随机双盲安慰剂对照2b期试验,评估自体肿瘤细胞疫苗gemogenovatucel-T作为一线维持治疗用于III/IV期卵巢癌患者的疗效与安全性。Gemogenovatucel-T耐受性良好,未出现3/4级毒性反应。

要点

  • Gemogenovatucel-T一线维持治疗卵巢癌未达到主要终点无复发生存期。
  • Gemogenovatucel-T组无3/4级毒性反应,安全性良好。
  • 建议按BRCA突变状态分层进一步研究gemogenovatucel-T。

核心结论

  • 一线使用gemogenovatucel-T免疫维持治疗耐受性良好,但未达到主要终点。
  • 建议在按BRCA突变状态分层的患者中进一步研究gemogenovatucel-T。

研究设计与样本

  • 随机、双盲、安慰剂对照的2b期试验,在美国25家医院开展。
  • 纳入18岁及以上、III/IV期高级别浆液性、子宫内膜样或透明细胞卵巢癌患者,在手术和5-8周期卡铂+紫杉醇化疗后达到临床完全缓解,ECOG状态0或1。
  • 患者按1:1随机分配至gemogenovatucel-T或安慰剂,按手术减瘤程度和新辅助vs辅助化疗分层。
  • Gemogenovatucel-T(每次注射1×10^7细胞)或安慰剂皮内注射,每月一次,至少4次至多12次。
  • 主要终点为无复发生存期,在符合方案人群中分析;安全性分析纳入所有接受至少一剂gemogenovatucel-T的患者。

主要发现

  • 2015年2月11日至2017年3月2日,22个中心共310例患者同意参与,217例被排除,91例接受gemogenovatucel-T(n=47)或安慰剂(n=44)并进行分析。
  • gemogenovatucel-T组未出现3级或4级毒性反应;安慰剂组2例患者发生5次3级毒性事件(关节痛、骨痛、全身肌无力、晕厥、呼吸困难)。
  • 7例患者(安慰剂组4例,gemogenovatucel-T组3例)发生11次严重不良事件;两组均未报告治疗相关死亡。

临床怎么用

  • gemogenovatucel-T作为一线维持治疗耐受性良好,但未显著改善无复发生存期,暂不推荐常规临床使用。
  • 可考虑在BRCA突变状态分层的人群中进一步开展临床研究。

局限性

  • 研究未达到主要终点,样本量较小(共91例可分析患者)。
  • 随访时间有限,中位随访约40个月。
  • 未按BRCA突变状态进行分层分析,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gemogenovatucel-T is an autologous tumour cell vaccine manufactured from harvested tumour tissue, which specifically reduces expression of furin and downstream TGF-β1 and TGF-β2. The aim of this study was to determine the safety and efficacy of gemogenovatucel-T in front-line ovarian cancer maintenance. METHODS: This randomised, double-blind, placebo-controlled, phase 2b trial involved 25 hospitals in the USA. Women aged 18 years and older with stage III/IV high-grade serous, endometrioid, or clear cell ovarian cancer in clinical complete response after a combination of surgery and five to eight cycles of chemotherapy involving carboplatin and paclitaxel, and an Eastern Cooperative Oncology Group status of 0 or 1 were eligible for inclusion in the study. Patients were randomly assigned (1:1) to gemogenovatucel-T or placebo by an independent third party interactive response system after successful screening using randomly permuted block sizes of two and four and stratified by extent of surgical cytoreduction and neoadjuvant versus adjuvant chemotherapy. Gemogenovatucel-T (1 × 107 cells per injection) or placebo was administered intradermally (one per month) for a minimum of four and up to 12 doses. Patients, investigators, and clinical staff were masked to patient allocation until after statistical analysis. The primary endpoint was recurrence-free survival, analysed in the per-protocol population. All patients who received at least one dose of gemogenovatucel-T were included in the safety analysis. The study is registered with ClinicalTrials.gov, NCT02346747. FINDINGS: Between Feb 11, 2015, and March 2, 2017, 310 patients consented to the study at 22 sites. 217 were excluded. 91 patients received gemogenovatucel-T (n=47) or placebo (n=44) and were analysed for safety and efficacy. The median follow-up from first dose of gemogenovatucel-T was 40·0 months (IQR 35·0-44·8) and from first dose of placebo was 39·8 months (35·5-44·6). Recurrence-free survival was 11·5 months (95% CI 7·5-not reached) for patients assigned to gemogenovatucel-T versus 8·4 months (7·9-15·5) for patients assigned to placebo (HR 0·69, 90% CI 0·44-1·07; one-sided p=0·078). Gemogenovatucel-T resulted in no grade 3 or 4 toxic effects. Two patients in the placebo group had five grade 3 toxic events, including arthralgia, bone pain, generalised muscle weakness, syncope, and dyspnea. Seven patients (four in the placebo group and three in the gemogenovatucel-T group) had 11 serious adverse events. No treatment-related deaths were reported in either of the groups. INTERPRETATION: Front-line use of gemogenovatucel-T immunotherapy as maintenance was well tolerated but the primary endpoint was not met. Further investigation of gemogenovatucel-T in patients stratified by BRCA mutation status is warranted. FUNDING: Gradalis.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Rocconi RP, Grosen EA, Ghamande SA, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020. PMID: 33271095. doi:10.1016/S1470-2045(20)30533-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。